Literature DB >> 114346

Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon.

T W Smith, B L Lloyd, N Spicer, E Haber.   

Abstract

To evaluate the relative merits of purified IgG and Fab preparations of defined specificity for potential clinical use, immunogenicity studies were carried out in baboon and rabbit experimental models. Distribution and elimination kinetics of purified sheep digoxin-specific IgG and Fab fragments were also studied following intravenous administration to baboons. Serial plasma and urine Fab concentrations were determined from trichloroacetic acid-precipitable 125I counts from pre-labelled preparations and also by measurement of the antibody's functional 3H-digoxin binding capacity. Results were compared with data obtained from IgG by 3H-digoxin binding. Kinetic data analysed by computer-fitted functions demonstrated that plasma Fab disappearance was best described by a tri-exponential function, whereas a bi-exponential function best described the IgG data. Initial distribution half-life (t 1/2) of Fab (0.28-0.32 hr) was considerably shorter than that of IgG (4.0 hr) and contributed a greater proportion of the total fall in plasma level over 24 hr. Fab elimination t 1/2 (9-13 hr) was also shorter than IgG (61 hr), but appreciably longer than earlier estimates in rabbits, guinea-pigs, rats and mice. The total volume of distribution of Fab was 8.7 times greater than that of IgG measured by the same method. Over the first 24 hr after administration 30-45% of administered Fab was recoverable in active form in urine, while 93% of total administered 125I counts from 125I-Fab preparations (bound and free) could be recovered. Less than 1% of administered IgG binding activity was recovered in urine during the initial 24 hr. The relative immunogenicities of sheep digoxin-specific IgG and Fab fragments were studied in six baboons. Both IgG and Fab elicited prompt immune responses when injected intramuscularly with Freund's complete adjuvant. Intravenous injection of soluble sheep IgG resulted in a prompt immune response in one baboon while repeated injections caused only a late, weak response in a second animal. Soluble sheep Fab fragments elicited only delayed and weak responses in the two baboons thus challenged. Further immunogenicity studies in ninteen rabbits showed significantly earlier and greater antibody responses to intravenously administered sheep IgG antigen than to Fab fragments derived from the same IgG population. These studies demonstrate that digoxin-specific Fab fragments undergo more rapid and extensive distribution to the extra vascular compartment and also more rapid renal excretion than IgG. Furthermore, Fab fragments are significantly less immunogenic than the parent IgG population. These data indicate potentially important therapeutic advantages for digoxin-specific Fab compared with IgG when administered for the reversal of life-threatening digitlis toxicity.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 114346      PMCID: PMC1537742     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

Review 1.  Clinical pharmacokinetics (second of two parts).

Authors:  D J Greenblatt; J Koch-Weser
Journal:  N Engl J Med       Date:  1975-11-06       Impact factor: 91.245

2.  Kinetics in interactions between antibodies and haptens.

Authors:  T W Smith; K M Skubitz
Journal:  Biochemistry       Date:  1975-04-08       Impact factor: 3.162

3.  Serum disappearance and catabolism of homologous immunoglobulin fragments in rats.

Authors:  W P Arend; F J Silverblatt
Journal:  Clin Exp Immunol       Date:  1975-12       Impact factor: 4.330

4.  Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies.

Authors:  T W Smith; E Haber; L Yeatman; V P Butler
Journal:  N Engl J Med       Date:  1976-04-08       Impact factor: 91.245

5.  Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

6.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

7.  The structure and function of immunoglobulin domains. IV. The distribution of some effector functions among the Cgamma2 and Cgamma3 homology regions of human immunoglobulin G1.

Authors:  D Yasmeen; J R Ellerson; K J Dorrington; R H Painter
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

8.  Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments.

Authors:  H R Ochs; T W Smith
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

9.  Sodium- and potassium-activated adenosine triphosphatase of the nasal salt gland of the duck (Anas platyrhynchos). Purification, characterization, and NH2-terminal amino acid sequence of the phosphorylating polypeptide.

Authors:  B E Hopkins; H Wagner; T W smith
Journal:  J Biol Chem       Date:  1976-07-25       Impact factor: 5.157

10.  Cellular mechanisms of protein metabolism in the nephron. I. The structural aspects of proteinuria; tubular absorption, droplet formation, and the disposal of proteins.

Authors:  J OLIVER; M MACDOWELL; Y C LEE
Journal:  J Exp Med       Date:  1954-06-01       Impact factor: 14.307

View more
  19 in total

Review 1.  Antivenom therapy in the Americas.

Authors:  K Heard; G F O'Malley; R C Dart
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

Review 2.  Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation.

Authors:  José María Gutiérrez; Guillermo León; Bruno Lomonte
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death.

Authors:  Ping Qiu; Xizhong Cui; Amisha Barochia; Yan Li; Charles Natanson; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2011-10-01       Impact factor: 6.206

4.  Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity.

Authors:  Christelle Mazuet; Julie Dano; Michel R Popoff; Christophe Créminon; Hervé Volland
Journal:  PLoS One       Date:  2010-08-26       Impact factor: 3.240

5.  Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma.

Authors:  D J Grimes; M R Bowles; J A Buttsworth; D B Thomson; P J Ravenscroft; P F Nixon; R F Whiting; S M Pond
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

6.  Kinetics of digoxin and anti-digoxin antibody fragments during treatment of digoxin toxicity.

Authors:  A J Sinclair; D S Hewick; P C Johnston; I H Stevenson; M Lemon
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

7.  Immunological probes in cardiovascular disease.

Authors:  E Haber
Journal:  Br Heart J       Date:  1982-01

Review 8.  Immunotherapy in the poisoned patient. Overview of present applications and future trends.

Authors:  J B Sullivan
Journal:  Med Toxicol       Date:  1986 Jan-Feb

9.  The influence of digoxin antibodies on digoxin disposition and effect: studies in guinea-pigs and HeLa cells.

Authors:  N M Griffiths; D S Hewick; J F Lamb; I H Stevenson
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

10.  The use of an enzyme-linked immunosorbent assay to study the disposition of sheep digoxin-specific immunoglobulin G and Fab fragments in the rat.

Authors:  P C Johnston; I H Stevenson; D S Hewick
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.